Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
Dana-Farber Cancer Institute Brigham and Women's Hospital Massachusetts General Hospital |
---|---|
Information provided by: | Dana-Farber Cancer Institute |
ClinicalTrials.gov Identifier: | NCT00268918 |
The main purpose of this study is to see if the study drug, PTK787, is safe and to find the highest dose that can be given safely without causing serious side effects.
Condition | Intervention | Phase |
---|---|---|
Ovarian Cancer Endometrial Cancer Cervical Cancer Fallopian Tube Cancer Peritoneal Cancer Breast Cancer |
Drug: Docetaxel Drug: PTK787 |
Phase I |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Historical Control, Single Group Assignment, Safety Study |
Official Title: | A Phase I Trial of Docetaxel and PTK787 in Metastatic Breast Cancer Patients and Recurrent or Refractory Gynecological Cancer Patients |
Estimated Enrollment: | 24 |
Study Start Date: | September 2005 |
Estimated Study Completion Date: | January 2010 |
Primary Completion Date: | January 2007 (Final data collection date for primary outcome measure) |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Female |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
United States, Massachusetts | |
Dana-Farber Cancer Institute | |
Boston, Massachusetts, United States, 02115 | |
Massachusetts General Hospital | |
Boston, Massachusetts, United States, 02114 |
Principal Investigator: | Susana M. Campos, MD | Dana-Farber Cancer Institute |
Responsible Party: | Dana-Farber Cancer Institute ( Susana M. Campos, MD ) |
Study ID Numbers: | 05-020 |
Study First Received: | December 21, 2005 |
Last Updated: | December 19, 2007 |
ClinicalTrials.gov Identifier: | NCT00268918 |
Health Authority: | United States: Food and Drug Administration |
PTK787 Metastatic breast cancer Refractory gynecological cancer |
Ovarian cancer Ovarian Neoplasms Skin Diseases Gonadal Disorders Genital Neoplasms, Female Uterine Diseases Breast Neoplasms Endocrine System Diseases Urogenital Neoplasms Ovarian Diseases Fallopian Tube Neoplasms Recurrence |
Vatalanib Fallopian Tube Diseases Docetaxel Genital Diseases, Female Endometrial Neoplasms Uterine Neoplasms Endocrinopathy Endometrial cancer Fallopian tube cancer Breast Diseases Endocrine Gland Neoplasms |
Neoplasms Neoplasms by Site Molecular Mechanisms of Pharmacological Action Antineoplastic Agents Therapeutic Uses |
Enzyme Inhibitors Protein Kinase Inhibitors Pharmacologic Actions Adnexal Diseases |